George Clinical Scientific Leaders boost recruitment for Phase 1 Patient Study

Utilizing key therapeutic knowledge leader networks as championed by George Clinical has again shown its effectiveness in boosting recruitment; this time for a Phase 1 renal patient trial. It is widely understood that the recruitment of patients into a Phase 1 trial can be fraught with difficulty. This difficulty arises from: A lack of established […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Scientific Leadership: Our Communication Framework

Background George Clinical provides scientific leadership to clinical trials, where peer-to-peer engagement from clinicians is leveraged to facilitate study operations. In the traditional study operations model, clinical research associates (CRAs) typically engage with site personnel, such as study coordinators, on a day-to-day basis. Principal investigators, whose expertise and seniority at the site’s operational hierarchy, is […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Renal Health: Recruitment Success in the Asia-Pacific

The Study George Clinical (GC) is collaborating with a global, research-based biopharmaceutical company to evaluate the effect of a new chemical entity in subjects with type 2 diabetes and nephropathy. George Clinical services GC is responsible for project management (PM) and monitoring throughout the Asia-Pacific. Other regions were managed by a separate contract research organization […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Oncology: Recruitment Success in China

The Study George Clinical (GC) collaborated with a mid-sized global pharmaceutical company to conduct a randomized trial comparing pain relief medication for patients with moderate to severe chronic cancer pain. George Clinical services GC was responsible for project management (PM) and monitoring across 26 sites in China. Study sites were located in Beijing, Changchun, Dalian, […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Oncology: Multiple services; one provider

With the support of George Clinical (GC), The George Institute (TGI) for Global Health conducted a longitudinal cohort study of approximately 9,500 hospital patients with a first time diagnosis of cancer. The study was conducted across eight countries, namely: Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand and Vietnam. The aim of the study was to […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Outstanding metrics achieved for a Phase III diabetes study in China

The World Health Organization estimates that 347 million people worldwide have diabetes, and that number is expected to continue increasing as more people move to urban cities and the population ages. Low and middle-income countries, like China and India, have been hit hardest with this disease and other NCDs. In 2010, the total number of […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

New treatment for the most serious form of stroke

Intracerebral hemorrhage is the most serious form of stroke with high rates of mortality and a low chance of recovery to functional independence. In Asia Pacific, it affects more than one million people annually, kills one third of them and leaves most survivors with disability. For reasons yet unknown, intracerebral hemorrhage is also more prevalent […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Developing clinical trials to meet the demands of 21st century diseases

Diseases that dominate the 21st century need a 21st century approach in the way we design and conduct clinical trials. To meet this need, George Clinical is primarily focused on large-scale studies with high-impact outcomes, particularly where smaller pre-registration trials need to be expanded to larger populations. George Clinical has been managing clinical trials in […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

COPD and its co-morbidities

COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]

Tweet about this on TwitterShare on FacebookShare on LinkedIn

Read More

Twitter Facebook LinkedIn